Evidence map›Paper›PMID 33515115›Full record

ArticleClinical rheumatology2021

Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study.

Kosuke Ebina, Toru Hirano, Yuichi Maeda, Wataru Yamamoto, Motomu Hashimoto, Koichi Murata, Akira Onishi, Sadao Jinno, Ryota Hara, Yonsu Son and 9 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 1 country.

Kosuke EbinaDepartment of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, Osaka, Japan. k-ebina@umin.ac.jp.ORCID http://orcid.org/0000-0002-2426-1024
Toru HiranoDepartment of Respiratory Medicine and Clinical Immunology, Osaka University, Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0001-8467-3154
Yuichi MaedaDepartment of Respiratory Medicine and Clinical Immunology, Osaka University, Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0002-6831-8205
Wataru YamamotoDepartment of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan.ORCID https://orcid.org/0000-0002-0810-4221
Motomu HashimotoDepartment of Advanced Medicine for Rheumatic diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-9241-060X
Koichi MurataDepartment of Advanced Medicine for Rheumatic diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-7896-3937
Akira OnishiDepartment of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Hyogo, Japan.ORCID https://orcid.org/0000-0002-3120-1273
Sadao JinnoDepartment of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Hyogo, Japan.ORCID https://orcid.org/0000-0003-3021-183X
Ryota HaraThe Center for Rheumatic Diseases, Nara Medical University, Nara, Japan.ORCID https://orcid.org/0000-0001-8000-3196
Yonsu SonFirst Department of Internal Medicine, Kansai Medical University, Osaka, Japan.ORCID https://orcid.org/0000-0001-7244-7715
Hideki AmuroFirst Department of Internal Medicine, Kansai Medical University, Osaka, Japan.ORCID https://orcid.org/0000-0002-7299-2884
Tohru TakeuchiDepartment of Internal Medicine (IV), Osaka Medical College, Osaka, Japan.ORCID https://orcid.org/0000-0002-0065-929X
Ayaka YoshikawaDepartment of Internal Medicine (IV), Osaka Medical College, Osaka, Japan.ORCID https://orcid.org/0000-0002-1927-1295
Masaki KatayamaDepartment of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan.ORCID https://orcid.org/0000-0002-0773-7238
Keiichi YamamotoInformation Technology Center, Wakayama Medical University Hospital, Wakayama, Japan.
Makoto HiraoDepartment of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0002-1408-7851
Yasutaka OkitaDepartment of Respiratory Medicine and Clinical Immunology, Osaka University, Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0003-3620-8412
Atsushi KumanogohDepartment of Respiratory Medicine and Clinical Immunology, Osaka University, Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0003-4749-7117
Ken NakataDepartment of Health and Sport Sciences, Osaka University, Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0002-8964-4229
The University of Osaka · JPKyoto University · JPKansai Medical University · JPKobe University · JPOsaka Medical and Pharmaceutical University · JPNara Medical University · JPOsaka Red Cross Hospital · JPOsaka University of Health and Sport Sciences · JPWakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this multicenter, retrospective study was to clarify the retention rates of sarilumab (SAR), baricitinib (BAR), and tofacitinib (TOF) in patients with rheumatoid arthritis (RA).

methodsPatients treated with either SAR (n = 62), BAR (n = 166), or TOF (n = 185) (females, 80.9%; age, 61.0 years; disease duration, 11.1 years; rheumatoid factor positivity, 84.4%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate, 4.3; concomitant prednisolone dose, 5.3 mg/day [47.0%] and methotrexate dose, 8.8 mg/week [58.4%]; biologics- or Janus kinase inhibitors-switched cases 78.4%) were included. The reasons for drug discontinuation were classified into 4 major categories (lack of effectiveness, toxic adverse events, non-toxic reasons, and remission) by each attending physician. The drug retention rate was estimated at 18 months using the Kaplan-Meier method and adjusted for potential confounders by Cox proportional hazards modeling.

resultsThe discontinuation rates of SAR, BAR, and TOF for the corresponding reasons were as follows, respectively: lack of effectiveness (15.7%, 15.6%, and 21.5%; P = 0.84), toxic adverse events (15.8%, 12.1%, and 12.3%; P = 0.35), non-toxic reasons (10.9%, 7.7%, and 6.8%; P = 0.35), and remission (0.0%, 2.8%, and 0.0%; P = 1.0). The overall retention rates excluding non-toxic reasons and remission were as follows: 68.8% for SAR, 72.5% for BAR, and 66.7% for TOF (P = 0.54).

conclusionsAfter adjustment by potent confounders, SAR, BAR, and TOF showed similar discontinuation rates due to lack of effectiveness and toxic adverse events. Key Points • This is the first retrospective multicenter study that aimed to clarify the retention rates and reasons for discontinuation of SAR, BAR, and TOF in patients with RA.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidPharmaceutical PreparationsAntibodies, Monoclonal, HumanizedAzetidinesCohort StudiesFemaleHumansMethotrexateMiddle AgedPiperidinesPurinesPyrazolesPyrimidinesPyrrolesRetrospective StudiesAntibodies, Monoclonal, HumanizedAntirheumatic AgentsAzetidinesbaricitinibMethotrexatePharmaceutical PreparationsPiperidinesPurinesPyrazolesPyrimidinesPyrrolessarilumabSulfonamidestofacitinibANSWER cohortBaricitinibDrug retentionRheumatoid arthritisSarilumabTofacitinib

Identifiers

PMID33515115
OpenAlexW3121233650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.